Multi-arm polymer prodrugs
View Patent ↗Provided herein are water-soluble prodrugs. The prodrugs of the invention comprise a water-soluble polymer having three or more arms, at least three of which are covalently attached to an active agent, e.g., a small molecule. The conjugates of the invention provide an optimal balance of polymer size and structure for achieving improved drug loading, since the conjugates of the invention possess three or more active agents releasably attached to a multi-armed water soluble polymer. The prodrugs of the invention are therapeutically effective, and exhibit improved properties in-vivo when compared to unmodified parent drug.
1. A multi-arm polymer prodrug having the structure:
wherein
R is an organic radical possessing from 3 to 150 carbon atoms,
Q is a linker, wherein R, when taken together with Q to form R(-Q-) q , is a residue of a polyol or a polythiol after removal of “q” hydroxyl or thiol protons, respectively, to form a point of attachment for POLY 1 ,
POLY 1 , is a water-soluble polymer selected from the group consisting of poly(alkylene glycol), poly(olefinic alcohol), poly(vinylpyrrolidone), poly(hydroxylalkyl -methacrylamide), poly(hydroxyalkyl-methacrylate), poly(α-hydroxy acid), poly(acrylic acid), poly(vinyl alcohol), polyphosphazene, polyoxazoline, poly(N-acryloylmorpholine), and copolymers or terpolymers thereof,
D is a camptothecin attached at its 10-, 11- or 20- ring position, and
q has a value from 3 to 50.
2. The multi-arm polymer prodrug of claim 1 , wherein R possesses from 3 to 50 carbon atoms.
3. The multi-arm polymer prodrug of claim 2 , wherein R possesses from 3 to 25 carbon atoms.
4. The multi-arm polymer prodrug of claim 3 , wherein R possesses a number of carbon atoms selected from the group consisting of 3, 4, 5, 6, 7, 8, 9, and 10.
5. The multi-arm polymer prodrug of claim 1 , wherein R is linear or cyclic.
6. The multi-armed polymer prodrug of claim 1 , wherein R, taken together with Q to form R(-Q-) q , is a residue of glycerol, trimethylolpropane, pentaerythritol, sorbitol, or glycerol oligomers after removal of “q” hydroxyl protons.
7. The multi-armed polymer prodrug of claim 6 , wherein POLY 1 is polyethylene glycol, the nominal average molecular weight of POLY 1 ranges from about 500 to about 20,000 daltons, X has an atom length of from 5 atoms to 25 atoms, and q is 4.
8. The multi-armed polymer prod rug of claim 1 , wherein Q is a sulfur atom.
9. The multi-armed polymer prodrug of claim 1 , wherein Q comprises a heteroatom in addition to said polyol oxygen or said polythiol sulfur.
10. The multi-armed polymer prodrug of claim 1 , wherein Q contains from 1 to 10 atoms.
11. The multi-armed polymer prodrug of claim 10 , wherein Q is an oxygen atom.
12. The multi-armed polymer prod rug of claim 1 , wherein POLY 1 is a polyethylene glycol.
13. The multi-armed polymer prodrug of claim 12 , wherein POLY 1 is linear.
14. The multi-armed polymer prodrug of claim 1 , wherein the nominal average molecular weight of POLY 1 ranges from 200 to 30,000 daltons.
15. The multi-armed polymer prodrug of claim 1 , wherein the nominal average molecular weight of POLY 1 ranges from 500 to 20,000 daltons.
16. The multi-armed polymer prodrug of claim 1 , wherein the nominal average molecular weight of the prodrug is greater than 20,000 daltons.
17. The multi-armed polymer prodrug of claim 1 wherein q ranges from 3 to 25.
18. The multi-armed polymer prodrug of claim 17 , wherein the value of q is selected from the group consisting of 3, 4, 5, 6, 7, 8, 9, and 10.
19. The multi-armed polymer prodrug of claim 17 , wherein each of said “q” polymer arms is
is the same.
20. The multi-armed polymer prodrug of claim 1 , wherein D is a camptothecin having a molecular weight of less than 800 daltons.
21. The multi-armed polymer prodrug of claim 1 , wherein D is a camptothecin compound having the structure:
wherein R 1 -R 5 are each independently selected from the group consisting of hydrogen; halo; acyl; alkyl (e.g., C1-C6 alkyl); substituted alkyl; alkoxy; substituted alkoxy; alkenyl; alkynyl; cycloalkyl; hydroxyl; cyano; nitro; azido; amido; hydrazine; amino; substituted amino; hydroxcarbonyl; alkoxycarbonyl; alkylcarbonyloxy; alkylcarbonylamino; carbamoyloxy; arylsulfonyloxy; alkylsulfonyloxy; —C(R 7 )═N—(O) i —R 8 wherein R 7 is H, alkyl, alkenyl, cycloalkyl, or aryl, i is 0 or 1, and R 8 is H, alkyl, alkenyl, cycloalkyl, or heterocycle; and R 9 C(O)O— wherein R 9 is halogen, amino, substituted amino, heterocycle, substituted heterocycle, or R 10 —O—(CH 2 ) m — where m is an integer of 1-10 and R 10 is alkyl, phenyl, substituted phenyl, cycloalkyl, substituted cycloalkyl, heterocycle, or substituted heterocycle; or
R 2 together with R 3 or R 3 together with R 4 form substituted or unsubstituted methylenedioxy, ethylenedioxy, or ethyleneoxy;
R 6 is H or OR′, wherein R′ is alkyl, alkenyl, cycloalkyl, haloalkyl, or hydroxyalkyl; and
L is the site of attachment.
22. The multi-armed polymer prodrug of claim 21 , wherein D has the structure:
23. The multi-armed polymer prodrug of claim 22 , having the structure:
where n ranges from 40 to 500.
24. The multi-armed polymer prodrug of claim 23 , wherein the overall nominal average molecular weight of the prodrug ranges from 20,000 to 80,000 daltons.
25. A multi-armed polymer prodrug of claim 24 , wherein said prodrug, when evaluated in a suitable animal model for solid tumor-type cancers and administered in a therapeutically effective amount, is effective to suppress tumor growth to an extent that is at least twice that observed for the unmodified anticancer agent when administered under the same conditions and at an equivalent dosage amount of anticancer agent over a time course of 30 days, based upon a comparison of tumor size.
26. A multi-armed polymer prod rug of claim 24 , wherein said prodrug, when evaluated in a suitable animal model for solid tumor-type cancers and administered in a therapeutically effective amount, is effective to suppress tumor growth to an extent that is at least 1.5 times that observed for the unmodified anticancer agent when administered under the same conditions and at an equivalent dosage amount of anticancer agent over a time course of 30 days, based upon a comparison of tumor size.
27. A multi-armed polymer prodrug of claim 24 , wherein said prodrug, when evaluated in a suitable animal model for solid tumor-type cancers and administered in a therapeutically effective amount, is effective to suppress tumor growth to an extent that is at least 1.5 times that observed for the unmodified anticancer agent when administered under the same conditions and at an equivalent dosage amount of anticancer agent over a time course of 60 days, based upon a comparison of tumor size.
28. A multi-armed polymer prodrug of claim 24 , wherein said prodrug, when evaluated in a suitable animal model for solid tumor-type cancers and administered in a therapeutically effective amount, is effective to suppress tumor growth to an extent that is at least 2 times that observed for the unmodified anticancer agent when administered under the same conditions and at an equivalent dosage amount of anticancer agent over a time course of 60 days, based upon a comparison of tumor size.
29. The multi-armed polymer prodrug of claim 1 , wherein D is SN-38.
30. The multi-armed polymer prodrug of claim 29 , wherein Q is oxygen and POLY 1 , is polyethylene glycol.
31. The multi-armed polymer prodrug of claim 30 , wherein R possesses a number of carbon atoms selected from the group consisting of 3, 4, 5, 6, 7, 8, 9, and 10.
32. The multi-armed polymer prodrug of claim 1 , wherein q is 4.
33. The multi-armed polymer prodrug of claim 1 .
34. A pharmaceutical composition comprising a multi-arm polymer prodrug of claim 1 .